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Introduction {#sec001}
============

Dengue virus (DENV) can cause dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), globally important mosquito-borne diseases \[[@pone.0138729.ref001], [@pone.0138729.ref002]\]. These are among the most serious epidemic arbovirus diseases and endemic in tropical and subtropical regions of the word. The causative viruses are members of the genus *Flavivirus* within the family Flaviviridae and can be grouped into four antigenically distinct serotypes (DENV1-4) that share 67--75% sequence homology \[[@pone.0138729.ref003], [@pone.0138729.ref004]\]. DENV is transmitted to humans through the bites of infected *Aedes aegypti* and *Aedes albopictus* mosquitoes. Nearly half of the world's population is under risk of contracting dengue. It is estimated that up to 390 million infections occur annually worldwide with approximately 96 million symptomatic cases \[[@pone.0138729.ref005]\]. Despite more than 60 years of effort, no licensed vaccine is currently available. Thus, the search for a safe and effective vaccine is growing more imperative.

Dengue is hyperendemic and has become a serious public health concern in China. The first outbreak of dengue was reported in Guangdong Province of China in 1978 \[[@pone.0138729.ref006], [@pone.0138729.ref007]\]. Since then, annual DENV epidemics have occurred, followed by a dengue epidemic in Guangxi, Fujian, Zhejiang, and other areas of China. In 2014, the most serious dengue epidemic in history occurred in Guangdong province of China with a total of 48,162 infected individuals \[[@pone.0138729.ref008]\]. This outbreak is considered an imported epidemic from neighboring Southeast Asian countries \[[@pone.0138729.ref009], [@pone.0138729.ref010]\]. In recent years, the scope of the epidemic is further expanding from the coastal city of China to inland cities. In 2013, an outbreak of DENV occurred in Yunnan province of China with more than 2,000 infected individuals \[[@pone.0138729.ref011]\]. A safe and effective dengue vaccine is urgent need in China.

CD8^+^ T-cell-mediated immunity plays an important role for eliminating intracellular pathogens. Thus, eliciting robust CD8^+^ T-cell immunity is the basis for many vaccines under development. Although DENV-specific CD8^+^ T-cell responses have been extensively studied, the vast majority of studies focused on immunopathogenic role of T-cells during DENV infection \[[@pone.0138729.ref012]--[@pone.0138729.ref014]\]. The viewpoint from these studies is that serotype cross-reactive CD8^+^ T-cells may contribute to the immunopathogenesis of DHF/DSS. Thus, the vast majority of dengue vaccine candidates are designed to produce protective neutralizing antibodies with less regard for cellular immune responses. However, direct evidence linking T-cells to increased viremia or DENV-related pathology has not been demonstrated. Notably, recent extensive studies have demonstrated a protective role of CD4^+^ and CD8^+^ T-cells against homologous or heterotypic DENV infection in murine models \[[@pone.0138729.ref015]--[@pone.0138729.ref020]\]. Specifically, these studies demonstrated that CD8^+^ T-cells can control viral replication \[[@pone.0138729.ref016]\], prevent antibody-dependent enhancement (ADE) of infection \[[@pone.0138729.ref019]\], and DENV-induced CNS disease \[[@pone.0138729.ref018]\].

These findings are consistent with the murine model data of a recent study supporting the concept of a protective role of T-cells against DENV infection in humans. The results of this study showed that the secondary DENV infection in humans was not significantly associated with disease severity \[[@pone.0138729.ref021]\]. Further, another recent study provided the first comprehensive map of the CD8^+^ T-cell response to DENV in humans and support a HLA-linked protective but not pathogenic role for CD8^+^ T-cells against DENV infection in humans \[[@pone.0138729.ref022]\]. Collectively, these findings strongly imply a protective role for CD8^+^ T-cells against severe DENV disease in humans. Based on these studies, it is inferred that the lack of induction of a robust DENV-specific T-cell response may be a reason for the results of a recent efficacy trial of the most advanced dengue vaccine candidate, a tetravalent live-attenuated chimeric vaccine (CYD) based on the 17D-attenuated yellow fever virus backbone that showed only partial protection despite the induction of DENV-specific neutralizing antibody to each serotype in most subjects \[[@pone.0138729.ref023]\]. This means that the roles of T-cells in the context of DENV vaccination should not be ignored, and it raises the possibility that T-cell responses against all DENV serotypes might be beneficial or even required for vaccine protective efficacy. The advent of a T-cell epitope--based vaccine may offer an alternative that avoids ADE. Considering the important role of serotype-specific CD8^+^ T-cells in controlling DENV infection, a novel strategy for developing prophylactic and therapeutic CD8^+^ T-cell epitope-based vaccines is needed. Therefore, a T-cell epitope-based universal vaccine that induces a broad dengue-specific, multifunctional, and cross-reactive CD8^+^ T-cell responses among all four DENV serotypes may be a more promising strategy against DENV infections.

The DENV genome consists of a single-stranded RNA of 10.7 kb in length. The open reading frame codes three structural proteins \[capsid (C) protein, preM protein, and envelope (E) protein\] and seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5) \[[@pone.0138729.ref024],[@pone.0138729.ref025]\]. It has been shown that CD8^+^ T cells preferentially target the NS3 and NS5 proteins, while CD4^+^ T cells preferentially target the E, C, and NS1 proteins \[[@pone.0138729.ref026]\]. Notably, NS5 is the largest and the most highly conserved protein encoded by the DENV genome, with approximately 67--82% amino acid sequence identity among the four DENV serotypes \[[@pone.0138729.ref027]\]. Thus, NS5 proteins could be used as a promising target in the design of a T-cell epitope-based vaccine to induce DENV-specific protective T-cell responses.

A necessary condition for a peptide to be a CD8^+^ T-cell epitope is that it binds to human leukocyte antigen (HLA) molecules. However, HLA molecules are extremely polymorphic with several thousand variants and can bind distinct sets of peptides \[[@pone.0138729.ref028]\]. Each HLA variant is expressed at vastly variable frequencies in different ethnic groups and geographic regions \[[@pone.0138729.ref029]\]. This means that it appears that an extremely large and impractical number of peptides would have to be selected to enable the development of a broadly protective multi-epitope vaccine. A large number of studies focused on predicting epitopes from the E, prM, NS1, NS3, or NS5 proteins allowed the identification of T-cell epitopes in DENV \[[@pone.0138729.ref030]--[@pone.0138729.ref036]\]. However, the CD8^+^ T-cell epitopes of the NS5 protein of DENV Chinese isolates linked with the class I HLA allele in Chinese population have been poorly revealed. Therefore, the identification of CD8^+^ T-cell epitopes that can induce protective DENV-specific T-cell responses by a feasible immunoinformatics approach is critical and urgent for the development of a T-cell epitope-based vaccine.

In this study, based on the distribution characteristics of HLA class I alleles in Chinese population, we identified putative CD8^+^ T-cell epitopes of NS5 protein of Chinese DENV isolates using various immunoinformatics approaches. Our results provide putative protective CD8^+^ T-cell epitope candidates or their combination for the development of a T-cell epitope-based universal vaccine to effectively prevent all four DENV serotypes that are endemic in China.

Materials and Methods {#sec002}
=====================

Retrieving the protein sequences {#sec003}
--------------------------------

The sequences of the NS5 protein from 155 Chinese isolates belong to all four serotypes of dengue virus (DENV-1, DENV-2, DENV-3 and DENV-4) were retrieved from the National Center for Biotechnology Information (NCBI) protein database (<http://www.ncbi.nlm.nih.gov/protein/>). The sequence of DENV-2 NS5 protein (accession number: KC131142.1) was used as an input for various bioinformatics tools for epitope prediction, antigenicity analysis and conservation analysis.

HLA genotypic frequency retrieval {#sec004}
---------------------------------

To improve population coverage of the CD8^+^ T-cell epitopes, it is important to screen epitopes restricted by highly prevalent HLA alleles. Genotypic frequencies of the HLA class I alleles that include HLA-A,-B and-C loci in Chinese population were retrieval from the major histocompatibility complex database (dbMHC) (<http://www.ncbi.nlm.nih.gov/projects/gv/mhc/main.fcgi?cmd=init>). For a broad coverage, HLA class I alleles with genotypic frequency \>3% in Chinese population were selected for CD8^+^ T-cell epitope prediction. This parameter setting covers the highly prevalent HLA-A,-B, and-C alleles found in Chinese population.

Epitope prediction {#sec005}
------------------

CD8^+^ T-cell epitope is the minimal amino acid sequence required for CD8^+^ T-cells activation and recognition by immune system receptors. Since the affinity of an epitope binds to the HLA molecule plays a vital role in determining its immunogenicity. Hence, high affinity between epitopes and HLA molecules tends to be associated with higher immune responsiveness. The prediction of CD8^+^ T-cell epitopes that interact with different HLA class I alleles were performed using the IEDB analysis resource (<http://tools.immuneepitope.org/mhci/>) Consensus tool \[[@pone.0138729.ref037]\], which combines predictions from ANN, aka NetMHC 3.4 \[[@pone.0138729.ref038]\]\[[@pone.0138729.ref039]\], SMM \[[@pone.0138729.ref040]\] and Comblib \[[@pone.0138729.ref041]\], if any corresponding predictor is available for the molecule. Otherwise, NetMHCpan is used. This choice was motivated by the expected predictive performance of the methods in decreasing order: Consensus \> ANN \> SMM \> NetMHCpan \> CombLib. For the IEDB-recommended method, a low percentile indicated strong binding affinity to HLA molecules. The threshold of percentile rank was set at 1 in this study \[[@pone.0138729.ref042]\]. Based on the representative length of peptides that bind to HLA molecules, peptide lengths of 8--11 amino acids were selected for the prediction of epitope-based peptides in this study.

Antigenicity analysis {#sec006}
---------------------

Antigenicity is a key characteristic of the epitope that is recognized by immune system cells and/or antibodies. Thus, the antigenicity of the predicted epitopes is one of the most important criteria for epitope-based vaccine assessment. Since some of the predicted epitopes may lose antigenicity when analyzed, to ensure that the predicted epitopes could serve as a good CD8^+^ T-cell epitope, all of the epitopes were screened to assess their antigenicity. VaxiJen v2.0 (<http://www.ddg-pharmfac.net/vaxijen/VaxiJen>), an online web server used to predict the effective antigens and subunit vaccines, was used to identify and reevaluate T-cell epitope antigenicity. The predicted epitopes were uploaded in a plain sequence format and the virus was chosen as the target organism. The threshold level of an antigen was set at 0.5. The Vaxijen server performed well with 87% accuracy at a threshold of 0.5 antigenic score for viruses \[[@pone.0138729.ref043]\]. VaxiJen v2.0 allows antigen classification based on the physicochemical properties of proteins without recourse to sequence alignment. Finally, the epitopes with an antigenic score \> 0.5 were selected as antigenic for the conservancy analysis.

Conservancy and population coverage analysis {#sec007}
--------------------------------------------

To obtain the universal T-cell epitopes of four DENV serotype variants, the conservancy of candidate epitopes should be considered prior to other criteria, even population coverage rate. As a universal T-cell epitope, it should be highly conserved in all viral variants. Hence, to determine the conservation level of the predicted epitopes among the NS5 protein sequences of the different DENV strains, the predicted epitopes were analyzed for their conservancy using the IEDB epitope conservancy tool (<http://tools.immuneepitope.org/tools/conservancy/iedb_input>) with a sequence identity threshold of 100%. The conservancy level of each potential epitope was calculated by seeking identities in all NS5 protein sequences of the four DENV serotype variants retrieved from the NCBI protein database. The epitopes that were 100% conserved in \>90% of the sequences analyzed in four serotypes were selected as candidate epitopes. These highly conserved epitopes were selected and used to determine the population coverage by the IEDB population coverage calculation tool (<http://tools.immuneepitope.org/tools/population/iedb_input>). Finally, all of the selected epitopes were analyzed for similarity with human proteome using the BLAST program (<http://www.ncbi.nlm.nih.gov/BLAST/>) to verify that they would not trigger autoimmunity.

Results and Discussion {#sec008}
======================

Retrial of NS5 protein sequences of four DENV serotypes {#sec009}
-------------------------------------------------------

The NS5 proteins sequence of all four DENV serotypes circulating in China were retrieved in FASTA format from the NCBI protein database. A total of 155 sequences of the NS5 protein of Chinese isolates of the four DENV serotypes was obtained ([S1 File](#pone.0138729.s001){ref-type="supplementary-material"}, [S2 File](#pone.0138729.s002){ref-type="supplementary-material"}, [S3 File](#pone.0138729.s003){ref-type="supplementary-material"} and [S4 File](#pone.0138729.s004){ref-type="supplementary-material"}) and used for the further epitope analysis.

HLA class I alleles analysis {#sec010}
----------------------------

Since specific HLA alleles are expressed at variable frequencies in different ethnic groups and different geographic regions. Therefore, HLA allele frequencies prevalent in dengue hyperendemic areas must be considered in vaccine design. Here we focused on DENV-specific T-cell epitopes that are associated with the highly prevalent HLA alleles in a Chinese population. To this end, the genotypic frequency of the highly prevalent HLA class I alleles found in this Chinese population (\>3%) that include HLA-A,-B, and-C loci were obtained from the dbMHC database. As a result, seven HLA-A alleles (A\*02:01, A\*02:03, A\*02:06, A\*02:07, A\*11:01, A\*24:02, and A\*33:03), eight HLA-B alleles (B\*13:01, B\*15:01, B\*15:02, B\*38:02, B\*40:01, B\*46:01, B\*51:01, and B\*58:01), and eight HLA-C alleles (C\*01:02, C\*03:02, C\*03:03, C\*03:04, C\*04:01, C\*08:01, C\*14:02, and C\*15:02) were obtained ([Table 1](#pone.0138729.t001){ref-type="table"}).

10.1371/journal.pone.0138729.t001

###### Frequency of HLA class I alleles (\>3%) in Chinese population.

![](pone.0138729.t001){#pone.0138729.t001g}

  Allele         Frequency
  -------------- -----------
  HLA-A\*02:01   0.053
  HLA-A\*02:03   0.108
  HLA-A\*02:06   0.035
  HLA-A\*02:07   0.094
  HLA-A\*11:01   0.277
  HLA-A\*24:02   0.172
  HLA-A\*33:03   0.115
  HLA-B\*13:01   0.082
  HLA-B\*15:01   0.044
  HLA-B\*15:02   0.071
  HLA-B\*38:02   0.071
  HLA-B\*40:01   0.149
  HLA-B\*46:01   0.115
  HLA-B\*51:01   0.050
  HLA-B\*58:01   0.089
  HLA-C\*01:02   0.169
  HLA-C\*03:02   0.087
  HLA-C\*03:03   0.041
  HLA-C\*03:04   0.128
  HLA-C\*04:01   0.044
  HLA-C\*08:01   0.126
  HLA-C\*14:02   0.036
  HLA-C\*15:02   0.037

Prediction and antigenic analysis of CD8^+^ T-cell epitopes {#sec011}
-----------------------------------------------------------

CD8^+^ T-cell responses play a substantial role in eliminating DENV infected cells that cannot be managed by antibody responses. An effective vaccine that can provide protection against dengue virus infection requires robust, broad, and multi-functional CD8^+^ T-cell responses. Therefore, the CD8^+^ T-cell epitopes that bind to different HLA class I alleles with varying affinities must first be identified. Here a large number of the antigenic epitopes with a high binding affinity score of \<1 percentile and an antigenicity score \> 0.5 were obtained from NS5 proteins of DENV Chinese isolates against HLA-A,-B, and-C alleles. Most epitopes bind with high affinity to single HLA-A,-B, or-C molecules. As a consequence, a total of 21 antigenic epitopes were obtained against the seven alleles of the HLA-A loci ([Table 2](#pone.0138729.t002){ref-type="table"}). A total of 53 antigenic epitopes were obtained against the eight alleles of the HLA-B loci ([Table 3](#pone.0138729.t003){ref-type="table"}), while 42 antigenic epitopes were obtained against the eight alleles of the HLA-C loci ([Table 4](#pone.0138729.t004){ref-type="table"}). Surprisingly, none of the epitopes bind to HLA-A\*02:07. Notably, some epitopes, like ^92^AMTDTTPF^99^ (B\*15:01, B\*15:02, B\*46:01, C\*03:02, and C\*15:02), ^515^MYFHRRDLRL^524^ (A\*24:02 and C\*14:02), ^225^WYMWLGAR^232^ (A\*33:03 and C\*04:01), ^234^LEFEALGF^241^ (B\*13:01 and C\*04:01), ^514^LMYFHRRDLRL^524^ (C\*01:02 and C\*14:02), and ^362^FTNMEAQL^369^ (C\*03:04 and C\*08:01) can be presented by multiple HLA molecules, suggesting that they can cover a broader population and may be better epitope vaccine candidates. Further, the potential of the epitope and HLA binding is essential in the assessment of the immunogenic potential of epitopes. Hence, as a ligand of the HLA-A molecule, epitopes ^225^WYMWLGAR^233^ and ^224^IWYMWLGARF^233^ presented by HLA-A\*24:02 were the best binders based on their 0.2 percentile. As ligands of HLA-B molecules, epitopes ^89^TQMAMTDTTPF^99^ and ^530^CSAVPSHW^537^, which were presented by HLA-B\*15:01 and HLA-B\*58:01, respectively, were the best binders based on their 0.1 percentile. Likewise, as a ligand of HLA-C molecule, epitope ^91^MAMTDTTPF^99^ presented by HLA-C\*03:02 was the best binder based on its 0.1 percentile. Additionally, HLA-A\*24:02 has the highest number of binding epitopes (9/21), followed by A\*33:03 (6/21) in the HLA-A allele. HLA-B\*13:01 and HLA-B\*58:01 presented the same most frequent epitopes (13/53), followed by B\*15:01 (12/53), B\*46:01 (12/53), B\*38:02 (11/53), and B\*15:02 (9/53) in the HLA-B alleles. Moreover, HLA-C\*04:01 presented the most frequent epitopes (17/42), followed by C\*14:02 (13/42), C\*01:02 (8/42), C\*03:02 (8/42), and C\*15:02 (7/42) in the HLA-C alleles. These calculations were made on the basis of HLA genotypic frequencies assuming non-linkage disequilibrium between HLA loci. Overall, these results provide *in silico* insight for class I HLA allele-restricted CD8^+^ T-cell epitopes against the NS5 protein of DENV in Chinese population.

10.1371/journal.pone.0138729.t002

###### HLA-A restricted epitopes of the NS5 protein and their binding affinity, antigenicity and conservation (in percentages) in different serotypes.

![](pone.0138729.t002){#pone.0138729.t002g}

  No.         Allele                 Start[^a^](#t002fn001){ref-type="table-fn"}   End[^a^](#t002fn001){ref-type="table-fn"}   Peptide length   Sequence            Method used                 Percentile rank   Antigenecity score   Percent of protein sequence matches at identity ≥ 100%
  ----------- ---------------------- --------------------------------------------- ------------------------------------------- ---------------- ------------------- --------------------------- ----------------- -------------------- --------------------------------------------------------
  001         HLA-A\*02:01           553                                           562                                         10               WMTTEDMLTV          Consensus (ann/smm)         1.0               0.6668               73.55% (114/155)
  002         HLA-A\*02:03           599                                           607                                         9                SLIGLTSRA           Consensus (ann/smm)         0.85              2.0423               68.39% (106/155)
  003         HLA-A\*02:03           553                                           562                                         10               WMTTEDMLTV          Consensus (ann/smm)         0.65              0.5568               73.55% (114/155)
  004         HLA-A\*02:06           553                                           562                                         10               WMTTEDMLTV          Consensus (ann/smm)         0.7               0.5568               73.55% (114/155)
  005         HLA-A\*11:01           338                                           346                                         9                TVMDIISRR           Consensus (ann/smm)         0.55              1.0053               10.97% (17/155)
  006         HLA-A\*11:01           125                                           133                                         9                KITAEWLWK           Consensus (ann/smm)         0.95              0.9815               10.97% (17/155)
  007         HLA-A\*11:01           317                                           326                                         10               AIFRLTYQNK          Consensus (ann/smm)         0.5               1.0707               1.94% (3/155)
  ***008***   ***HLA-A\*11*:*01***   ***200***                                     ***210***                                   ***11***         ***CVYNMMGKREK***   ***Consensus (ann/smm)***   ***0*.*65***      ***0*.*6848***       ***94*.*84% (147/155)***
  009         HLA-A\*24:02           225                                           233                                         9                WYMWLGARF           Consensus (ann/smm)         0.2               0.9423               32.26% (50/155)
  010         HLA-A\*24:02           224                                           233                                         10               IWYMWLGARF          Consensus (ann/smm)         0.2               0.7264               32.26% (50/155)
  011         HLA-A\*24:02           227                                           236                                         10               MWLGARFLEF          Consensus (ann/smm)         0.25              1.0434               32.26% (50/155)
  012         HLA-A\*24:02           225                                           234                                         10               WYMWLGARFL          Consensus (ann/smm)         0.3               0.6068               32.26% (50/155)
  013         HLA-A\*24:02           544                                           553                                         10               TWSIHATHEW          Consensus (ann/smm)         0.5               1.1355               9.03% (14/155)
  ***014***   ***HLA-A\*24*:*02***   ***515***                                     ***524***                                   ***10***         ***MYFHRRDLRL***    ***Consensus (ann/smm)***   ***0*.*55***      ***1*.*6075***       ***98*.*71% (153/155)***
  015         HLA-A\*24:02           449                                           458                                         10               GWNDWTQVPF          Consensus (ann/smm)         0.65              0.9735               9.68% (15/155)
  016         HLA-A\*24:02           232                                           241                                         10               RFLEFEALGF          Consensus (ann/smm)         0.95              1.7726               32.26% (50/155)
  017         HLA-A\*24:02           226                                           236                                         11               YMWLGARFLEF         Consensus (ann/smm)         0.95              1.0316               32.26% (50/155)
  018         HLA-A\*33:03           513                                           520                                         8                SLMYFHRR            netmhcpan                   0.2               1.5676               80.00% (124/155)
  ***019***   ***HLA-A\*33*:*03***   ***225***                                     ***232***                                   ***8***          ***WYMWLGAR***      ***netmhcpan***             ***0*.*4***       ***1*.*2415***       ***99*.*35% (154/155)***
  020         HLA-A\*33:03           512                                           519                                         8                WSLMYFHR            netmhcpan                   0.4               0.7229               80.00% (124/155)
  ***021***   ***HLA-A\*33*:*03***   ***516***                                     ***523***                                   ***8***          ***YFHRRDLR***      ***netmhcpan***             ***0*.*4***       ***1*.*6748***       ***98*.*71% (153/155)***
  022         HLA-A\*33:03           395                                           402                                         8                NWLVRVGR            netmhcpan                   0.6               1.2717               3.87% (6/155)
  ***023***   ***HLA-A\*33*:*03***   ***284***                                     ***291***                                   ***8***          ***DTAGWDTR***      ***netmhcpan***             ***0*.*7***       ***1*.*7765***       ***98*.*06% (152/155)***

^a^The epitopes location in NS5 protein are from accession number: KC131142.1.

Bold and italic- indicates the percentage of epitope that is 100% conserved in more than 90% of the sequences analysed in four serotypes.

10.1371/journal.pone.0138729.t003

###### HLA-B restricted epitopes of the NS5 protein and their binding affinity, antigenicity and conservation (in percentages) in different serotypes.

![](pone.0138729.t003){#pone.0138729.t003g}

  No.         Allele               Start[^a^](#t003fn001){ref-type="table-fn"}   End[^a^](#t003fn001){ref-type="table-fn"}   Peptide length   Sequence           Method used                              Percentile rank   Antigenecity score   Percent of protein sequence matches at identity ≥ 100%
  ----------- -------------------- --------------------------------------------- ------------------------------------------- ---------------- ------------------ ---------------------------------------- ----------------- -------------------- --------------------------------------------------------
  ***001***   ***HLA-B\*13:01***   ***234***                                     ***241***                                   ***8***          ***LEFEALGF***     ***netmhcpan***                          ***0.2***         ***2.1459***         ***96.77% (150/155)***
  002         HLA-B\*13:01         128                                           135                                         8                AEWLWKEL           netmhcpan                                0.3               0.8381               10.97% (17/155)
  003         HLA-B\*13:01         510                                           517                                         8                QMWSLMYF           netmhcpan                                0.4               0.5350               80.65% (125/155)
  004         HLA-B\*13:01         226                                           233                                         8                YMWLGARF           netmhcpan                                0.6               0.8453               32.26% (50/155)
  005         HLA-B\*13:01         371                                           378                                         8                RQMEGEGV           netmhcpan                                0.8               0.5155               77.42% (120/155)
  006         HLA-B\*13:01         19                                            26                                          8                SETPNLDI           netmhcpan                                0.9               0.5435               5.16% (8/155)
  007         HLA-B\*13:01         234                                           242                                         9                LEFEALGFL          netmhcpan                                0.5               1.7009               78.71% (122/155)
  008         HLA-B\*13:01         19                                            27                                          9                SETPNLDII          netmhcpan                                0.7               0.5209               5.16% (8/155)
  009         HLA-B\*13:01         520                                           529                                         10               RDLRLAANAI         netmhcpan                                0.7               0.8520               29.03% (45/155)
  010         HLA-B\*13:01         382                                           391                                         10               IQHLTVTEEI         netmhcpan                                0.9               0.7084               9.68% (15/155)
  011         HLA-B\*13:01         580                                           589                                         10               VESWEEIPYL         netmhcpan                                1                 0.5190               10.97% (17/155)
  012         HLA-B\*13:01         89                                            99                                          11               TQMAMTDTTPF        netmhcpan                                0.2               0.9856               77.42% (120/155)
  013         HLA-B\*13:01         226                                           236                                         11               YMWLGARFLEF        netmhcpan                                0.3               1.0316               32.26% (50/155)
  ***014***   ***HLA-B\*15:01***   ***92***                                      ***99***                                    ***8***          ***AMTDTTPF***     ***ann***                                ***0.2***         ***0.6985***         ***98.06% (152/155)***
  015         HLA-B\*15:01         226                                           233                                         8                YMWLGARF           ann                                      0.5               0.8453               32.26% (50/155)
  016         HLA-B\*15:01         142                                           149                                         8                RMCTREEF           ann                                      0.6               1.0232               10.97% (17/155)
  017         HLA-B\*15:01         510                                           517                                         8                QMWSLMYF           ann                                      0.6               0.5350               80.65% (125/155)
  018         HLA-B\*15:01         91                                            99                                          9                MAMTDTTPF          Consensus (ann/comblib_sidney2008/smm)   0.2               0.6735               77.42% (120/155)
  019         HLA-B\*15:01         228                                           236                                         9                WLGARFLEF          Consensus (ann/comblib_sidney2008/smm)   0.6               1.5566               32.26% (50/155)
  020         HLA-B\*15:01         90                                            99                                          10               QMAMTDTTPF         Consensus (ann/smm)                      0.3               0.9860               77.42% (120/155)
  021         HLA-B\*15:01         89                                            99                                          11               TQMAMTDTTPF        ann                                      0.1               0.9856               77.42% (120/155)
  022         HLA-B\*15:01         226                                           236                                         11               YMWLGARFLEF        ann                                      0.3               1.0316               32.26% (50/155)
  023         HLA-B\*15:01         330                                           340                                         11               VQRPTPRGTVM        ann                                      0.3               0.8415               9.68% (15/155)
  024         HLA-B\*15:02         226                                           233                                         8                YMWLGARF           ann                                      0.2               0.8453               32.26% (50/155)
  025         HLA-B\*15:02         622                                           629                                         8                SLIGNEEY           ann                                      0.3               0.8841               10.32% (16/155)
  ***026***   ***HLA-B\*15:02***   ***92***                                      ***99***                                    ***8***          ***AMTDTTPF***     ***ann***                                ***0.7***         ***0.6985***         ***98.06% (152/155)***
  027         HLA-B\*15:02         510                                           517                                         8                QMWSLMYF           ann                                      1                 0.5350               80.65% (125/155)
  028         HLA-B\*15:02         90                                            99                                          10               QMAMTDTTPF         ann                                      0.3               0.9860               77.42% (120/155)
  029         HLA-B\*15:02         89                                            99                                          11               TQMAMTDTTPF        ann                                      0.3               0.9856               77.42% (120/155)
  030         HLA-B\*15:02         226                                           239                                         11               YMWLGARFLEF        ann                                      0.3               1.0316               32.26% (50/155)
  031         HLA-B\*15:02         622                                           632                                         11               SLIGNEEYTDY        ann                                      0.3               0.9393               10.32% (16/155)
  032         HLA-B\*15:02         330                                           340                                         11               VQRPTPRGTVM        ann                                      0.9               0.8415               9.68% (15/155)
  033         HLA-B\*38:02         124                                           131                                         8                MKITAEWL           netmhcpan                                1                 0.5377               10.97% (17/155)
  ***034***   ***HLA-B\*38:02***   ***262***                                     ***269***                                   ***8***          ***LHKLGYIL***     ***netmhcpan***                          ***1***           ***0.7094***         ***92.90% (144/155)***
  035         HLA-B\*38:02         383                                           391                                         9                QHLTVTEEI          netmhcpan                                0.2               0.9107               9.68% (15/155)
  036         HLA-B\*38:02         42                                            50                                          9                WHYDQDHPY          netmhcpan                                0.4               0.5520               9.03% (14/155)
  037         HLA-B\*38:02         91                                            99                                          9                MAMTDTTPF          netmhcpan                                0.8               0.6735               77.42% (120/155)
  038         HLA-B\*38:02         89                                            99                                          11               TQMAMTDTTPF        netmhcpan                                0.3               0.9856               77.42% (120/155)
  039         HLA-B\*38:02         383                                           393                                         11               QHLTVTEEIAV        netmhcpan                                0.4               0.8018               9.68% (15/155)
  040         HLA-B\*38:02         535                                           545                                         11               SHWVPTSRTTW        netmhcpan                                0.5               1.4792               10.97% (17/155)
  041         HLA-B\*38:02         626                                           636                                         22               NEEYTDYMPSM        netmhcpan                                0.8               0.6913               10.32% (16/155)
  042         HLA-B\*38:02         480                                           490                                         11               NQDELIGRARI        netmhcpan                                0.9               0.6578               14.19% (22/155)
  043         HLA-B\*38:02         226                                           236                                         11               YMWLGARFLEF        netmhcpan                                1                 1.0316               32.26% (50/155)
  044         HLA-B\*40:01         250                                           257                                         8                RENSLSGV           Consensus (ann/smm)                      0.75              0.8542               28.39% (44/155)
  045         HLA-B\*40:01         234                                           242                                         9                LEFEALGFL          Consensus (ann/smm)                      0.2               1.7009               78.71% (122/155)
  046         HLA-B\*40:01         19                                            27                                          9                SETPNLDII          Consensus (ann/smm)                      0.85              0.5209               5.16% (8/155)
  047         HLA-B\*40:01         580                                           589                                         10               VESWEEIPYL         Consensus (ann/smm)                      0.5               0.5109               10.97% (17/155)
  048         HLA-B\*40:01         182                                           191                                         10               WELVDKERNL         Consensus (ann/smm)                      0.85              1.4932               10.97% (17/155)
  ***049***   ***HLA-B\*46:01***   ***92***                                      ***99***                                    ***8***          ***AMTDTTPF***     ***ann***                                ***0.3***         ***0.6985***         ***98.06% (152/155)***
  050         HLA-B\*46:01         226                                           233                                         8                YMWLGARF           ann                                      0.4               0.8453               32.26% (50/155)
  051         HLA-B\*46:01         510                                           517                                         8                QMWSLMYF           ann                                      0.7               0.5350               80.65% (125/155)
  052         HLA-B\*46:01         467                                           474                                         8                IMKDGRVL           ann                                      1                 0.6354               10.97% (17/155)
  053         HLA-B\*46:01         629                                           636                                         8                YTDYMPSM           ann                                      1                 0.8868               10.97% (17/155)
  054         HLA-B\*46:01         91                                            99                                          9                MAMTDTTPF          Consensus (ann/smm)                      0.2               0.6735               77.42% (120/155)
  055         HLA-B\*46:01         272                                           280                                         9                VSKKEGGAM          Consensus (ann/smm)                      0.65              0.5314               10.97% (17/155)
  056         HLA-B\*46:01         248                                           257                                         10               FSRENSLSGV         ann                                      0.7               1.2193               28.39% (44/155)
  057         HLA-B\*46:01         90                                            99                                          10               QMAMTDTTPF         ann                                      0.8               0.9860               77.42% (120/155)
  058         HLA-B\*46:01         78                                            87                                          10               LTKPWDVIPM         ann                                      0.9               0.9964               32.26% (50/155)
  059         HLA-B\*46:01         226                                           236                                         11               YMWLGARFLEF        ann                                      0.2               1.0316               32.26% (50/155)
  060         HLA-B\*46:01         89                                            99                                          11               TQMAMTDTTPF        ann                                      0.8               0.9856               77.42% (120/155)
  061         HLA-B\*51:01         85                                            93                                          9                IPMVTQMAM          Consensus (ann/comblib_sidney2008/smm)   0.5               0.5370               10.97% (17/155)
  062         HLA-B\*51:01         80                                            88                                          9                KPWDVIPMV          Consensus (ann/comblib_sidney2008/smm)   0.8               1.2766               32.26% (50/155)
  ***063***   ***HLA-B\*51:01***   ***538***                                     ***547***                                   ***10***         ***VPTSRTTWSI***   ***Consensus (ann/smm)***                ***0.3***         ***1.0517***         ***90.97% (141/155)***
  064         HLA-B\*58:01         530                                           537                                         8                CSAVPSHW           ann                                      0.1               0.8475               10.97% (17/155)
  065         HLA-B\*58:01         125                                           132                                         8                KITAEWLW           ann                                      0.3               1.0187               10.97% (17/155)
  066         HLA-B\*58:01         123                                           130                                         8                LMKITAEW           ann                                      1                 1.0313               10.97% (17/155)
  067         HLA-B\*58:01         545                                           553                                         9                KLMKITAEW          Consensus (ann/comblib_sidney2008/smm)   0.2               1.0764               10.97% (17/155)
  068         HLA-B\*58:01         91                                            99                                          9                MAMTDTTPF          Consensus (ann/comblib_sidney2008/smm)   0.3               0.6735               77.42% (120/155)
  069         HLA-B\*58:01         124                                           132                                         9                MKITAEWLW          Consensus (ann/comblib_sidney2008/smm)   0.3               0.7346               10.97% (17/155)
  070         HLA-B\*58:01         601                                           609                                         9                IGLTSRATW          Consensus (ann/comblib_sidney2008/smm)   0.4               1.5513               68.39% (106/155)
  071         HLA-B\*58:01         621                                           629                                         9                RSLIGNEEY          Consensus (ann/comblib_sidney2008/smm)   0.9               0.9167               10.32% (16/155)
  072         HLA-B\*58:01         544                                           553                                         10               TWSIHATHEW         Consensus (ann/smm)                      0.6               1.1355               9.03% (14/155)
  073         HLA-B\*58:01         33                                            42                                          10               KIKQEHETSW         Consensus (ann/smm)                      0.6               0.9160               10.97% (17/155)
  074         HLA-B\*58:01         123                                           132                                         10               LMKITAEWLW         Consensus (ann/smm)                      0.65              0.9159               10.97% (17/155)
  075         HLA-B\*58:01         237                                           247                                         11               EALGFLNEDHW        Consensus (ann/smm)                      0.75              1.0740               77.42% (120/155)
  076         HLA-B\*58:01         599                                           609                                         11               SLIGLTSRATW        Consensus (ann/smm)                      0.95              1.7930               68.39% (106/155)

^a^The epitopes location in NS5 protein are from accession number: KC131142.1.

Bold and italic- indicates the percentage of epitope that is 100% conserved in more than 90% of the sequences analysed in four serotypes.

10.1371/journal.pone.0138729.t004

###### HLA-C restricted epitopes of the NS5 protein and their binding affinity, antigenicity and conservation (in percentages) in different serotypes.

![](pone.0138729.t004){#pone.0138729.t004g}

  No.         Allele                 Start[^a^](#t004fn001){ref-type="table-fn"}   End[^a^](#t004fn001){ref-type="table-fn"}   Peptide length   Sequence            Method used                 Percentile rank   Antigenecity score   Percent of protein sequence matches at identity ≥100%
  ----------- ---------------------- --------------------------------------------- ------------------------------------------- ---------------- ------------------- --------------------------- ----------------- -------------------- -------------------------------------------------------
  001         HLA-C\*01:02           629                                           636                                         8                YTDYMPSM            netmhcpan                   0.6               0.8868               10.97% (17/155)
  002         HLA-C\*01:02           91                                            99                                          9                MAMTDTTPF           netmhcpan                   0.2               0.6735               77.42% (120/155)
  003         HLA-C\*01:02           85                                            93                                          9                IPMVTQMAM           netmhcpan                   0.7               0.5370               10.97% (17/155)
  ***004***   ***HLA-C\*01*:*02***   ***514***                                     ***522***                                   ***9***          ***LMYFHRRDL***     ***netmhcpan***             ***0*.*8***       ***1*.*5116***       ***98*.*71% (153/155)***
  005         HLA-C\*01:02           84                                            93                                          10               VIPMVTQMAM          netmhcpan                   0.6               0.7337               10.97% (17/155)
  006         HLA-C\*01:02           513                                           522                                         10               SLMYFHRRDL          netmhcpan                   0.7               1.4737               80.00% (124/155)
  007         HLA-C\*01:02           226                                           236                                         11               YMWLGARFLEF         netmhcpan                   0.8               1.0316               32.26% (50/155)
  ***008***   ***HLA-C\*01*:*02***   ***514***                                     ***524***                                   ***11***         ***LMYFHRRDLRL***   ***netmhcpan***             ***0*.*9***       ***1*.*5932***       ***98*.*71% (153/155)***
  009         HLA-C\*03:02           629                                           636                                         8                YTDYMPSM            netmhcpan                   0.4               0.8868               10.97% (17/155)
  ***010***   ***HLA-C\*03*:*02***   ***92***                                      ***99***                                    ***8***          ***AMTDTTPF***      ***netmhcpan***             ***0*.*9***       ***0*.*6985***       ***98*.*06% (152/155)***
  011         HLA-C\*03:02           226                                           233                                         8                YMWLGARF            netmhcpan                   1                 0.8453               32.26% (50/155)
  012         HLA-C\*03:02           91                                            99                                          9                MAMTDTTPF           netmhcpan                   0.1               0.6735               77.42% (120/155)
  013         HLA-C\*03:02           615                                           623                                         9                TAINQVRSL           netmhcpan                   0.7               0.6391               10.97% (17/155)
  014         HLA-C\*03:02           545                                           554                                         10               WSIHATHEWM          netmhcpan                   0.8               0.8628               9.03% (14/155)
  015         HLA-C\*03:02           226                                           236                                         11               YMWLGARFLEF         netmhcpan                   0.5               1.0316               32.26% (50/155)
  016         HLA-C\*03:02           89                                            99                                          11               TQMAMTDTTPF         netmhcpan                   1                 0.9856               77.42% (120/155)
  017         HLA-C\*03:03           615                                           623                                         9                TAINQVRSL           Consensus (ann/smm)         0.6               0.6391               10.97% (17/155)
  018         HLA-C\*03:03           501                                           511                                         11               TACLGKSYAQM         ann                         0.9               0.6954               29.03% (45/155)
  019         HLA-C\*03:03           474                                           484                                         11               LVVPCRNQDEL         ann                         1                 1.0079               14.19% (22/155)
  020         HLA-C\*03:04           629                                           636                                         8                YTDYMPSM            netmhcpan                   0,5               0.8868               10.97% (17/155)
  ***021***   ***HLA-C\*03*:*04***   ***362***                                     ***369***                                   ***8***          ***FTNMEAQL***      ***netmhcpan***             ***1***           ***0*.*7649***       ***94*.*84% (147/155)***
  022         HLA-C\*03:04           91                                            99                                          9                MAMTDTTPF           netmhcpan                   0.2               0.6735               77.42% (120/155)
  023         HLA-C\*03:04           615                                           623                                         9                TAINQVRSL           netmhcpan                   0.4               0.6391               10.97% (17/155)
  024         HLA-C\*04:01           287                                           294                                         8                GWDTRITL            ann                         0.2               1.6194               10.97% (17/155)
  025         HLA-C\*04:01           582                                           589                                         8                SWEEIPYL            ann                         0.4               0.9783               10.97% (17/155)
  ***026***   ***HLA-C\*04*:*01***   ***225***                                     ***232***                                   ***8***          ***WYMWLGAR***      ***ann***                   ***0*.*5***       ***1*.*2415***       ***99*.*35% (154/155)***
  027         HLA-C\*04:01           226                                           233                                         8                YMWLGARF            ann                         0.5               0.8453               32.26% (50/155)
  ***028***   ***HLA-C\*04*:*01***   ***234***                                     ***241***                                   ***8***          ***LEFEALGF***      ***ann***                   ***1***           ***2*.*1459***       ***96*.*77% (150/155)***
  029         HLA-C\*04:01           287                                           295                                         9                GWDTRITLE           Consensus (ann/smm)         0.25              1.4743               10.97% (17/155)
  030         HLA-C\*04:01           225                                           233                                         9                WYMWLGARF           Consensus (ann/smm)         0.75              0.9423               32.26% (50/155)
  ***031***   ***HLA-C\*04*:*01***   ***361***                                     ***369***                                   ***9***          ***TFTNMEAQL***     ***Consensus (ann/smm)***   ***1***           ***0*.*8131***       ***94*.*84% (147/155)***
  032         HLA-C\*04:01           450                                           458                                         9                WNDWTQVPF           Consensus (ann/smm)         0.6               0.9685               9.68% (15/155)
  033         HLA-C\*04:01           225                                           234                                         10               WYMWLGARFL          ann                         0.2               0.6068               32.26% (50/155)
  034         HLA-C\*04:01           449                                           458                                         10               GWNDWTQVPF          ann                         0.3               0.9735               9.68% (15/155)
  035         HLA-C\*04:01           224                                           233                                         10               IWYMWLGARF          ann                         0.6               0.7264               32.26% (50/155)
  036         HLA-C\*04:01           223                                           233                                         11               AIWYMWLGARF         ann                         0.7               0.5658               32.26% (50/155)
  037         HLA-C\*04:01           89                                            99                                          11               TQMAMTDTTPF         ann                         0.9               0.9856               77.42% (120/155)
  038         HLA-C\*04:01           225                                           235                                         11               WYMWLGARFLE         ann                         0.9               0.6782               32.26% (50/155)
  039         HLA-C\*04:01           226                                           236                                         11               YMWLGARFLEF         ann                         0.9               1.0316               32.26% (50/155)
  040         HLA-C\*04:01           582                                           592                                         11               SWEEIPYLGKR         ann                         0.9               1.2892               10.97% (17/155)
  041         HLA-C\*08:01           629                                           636                                         8                YTDYMPSM            netmhcpan                   0.2               0.8868               10.97% (17/155)
  ***042***   ***HLA-C\*08*:*01***   ***362***                                     ***369***                                   ***8***          ***FTNMEAQL***      ***netmhcpan***             ***0*.*9***       ***0*.*7649***       ***94*.*84% (147/155)***
  043         HLA-C\*08:01           91                                            99                                          9                MAMTDTTPF           netmhcpan                   0.3               0.6735               77.42% (120/155)
  ***044***   ***HLA-C\*14*:*02***   ***515***                                     ***522***                                   ***8***          ***MYFHRRDL***      ***ann***                   ***0*.*2***       ***1*.*5109***       ***98*.*71% (153/155)***
  045         HLA-C\*14:02           247                                           254                                         8                WFSRENSL            ann                         0.8               0.5342               28.39% (44/155)
  046         HLA-C\*14:02           232                                           239                                         8                RFLEFEAL            ann                         0.9               1.2524               32.26% (50/155)
  047         HLA-C\*14:02           43                                            50                                          8                HYDQDHPY            ann                         1                 0.6739               9.03% (14/155)
  048         HLA-C\*14:02           226                                           233                                         8                YMWLGARF            ann                         1                 0.8453               32.26% (50/155)
  049         HLA-C\*14:02           628                                           636                                         9                EYTDYMPSM           Consensus (ann/smm)         0.35              0.8846               10.97% (17/155)
  050         HLA-C\*14:02           225                                           233                                         9                WYMWLGARF           Consensus (ann/smm)         0.65              0.9423               32.26% (50/155)
  ***051***   ***HLA-C\*14*:*02***   ***515***                                     ***524***                                   ***10***         ***MYFHRRDLRL***    ***ann***                   ***0*.*2***       ***1*.*6075***       ***98*.*71% (153/155)***
  052         HLA-C\*14:02           225                                           234                                         10               WYMWLGARFL          ann                         0.3               0.6068               32.26% (50/155)
  053         HLA-C\*14:02           84                                            93                                          10               VIPMVTQMAM          ann                         1                 0.7337               10.97% (17/155)
  054         HLA-C\*14:02           226                                           236                                         11               YMWLGARFLEF         ann                                           1.0316               32.26% (50/155)
  ***055***   ***HLA-C\*14*:*02***   ***514***                                     ***524***                                   ***11***         ***LMYFHRRDLRL***   ***ann***                   ***0*.*9***       ***1*.*5932***       ***98*.*71% (153/155)***
  056         HLA-C\*14:02           89                                            99                                          11               TQMAMTDTTPF         ann                         1                 0.9856               77.42% (120/155)
  057         HLA-C\*15:02           226                                           233                                         8                YMWLGARF            ann                         0.2               0.8453               32.26% (50/155)
  058         HLA-C\*15:02           622                                           629                                         8                SLIGNEEY            ann                         0.3               0.8841               10.32% (16/155)
  ***059***   ***HLA-C\*15*:*02***   ***92***                                      ***99***                                    ***8***          ***AMTDTTPF***      ***ann***                   ***0*.*7***       ***0*.*6985***       ***98*.*06% (152/155)***
  060         HLA-C\*15:02           510                                           517                                         8                QMWSLMYF            ann                         1                 0.5350               80.65% (125/155)
  061         HLA-C\*15:02           362                                           370                                         9                FTNMEAQLI           Consensus (ann/smm)         0.25              0.7034               29.68% (46/155)
  062         HLA-C\*15:02           154                                           162                                         9                RSNAALGAI           Consensus (ann/smm)         0.6               1.0339               9.03% (14/155)
  063         HLA-C\*15:02           360                                           370                                         11               NTFTNMEAQLI         ann                         0.9               0.7529               29.68% (46/155)

^a^The epitopes location in NS5 protein are from accession number: KC131142.1.

Bold and italic- indicates the percentage of epitope that is 100% conserved in more than 90% of the sequences analysed in four serotypes.

Conservancy and population coverage of CD8^+^ T-cell epitopes {#sec012}
-------------------------------------------------------------

As an effective vaccine formulation, the epitope-based universal vaccine must include highly conserved CD8^+^ T-cell epitopes among all DENV serotypes to induce cross-reactive T-cell responses based on the fact that the conserved epitope candidates are more likely to confer cross-protection between pathogen variants. Here, conservancy analysis revealed a total of 14 highly conserved epitopes with ≥90% protein sequence matching in a total of 155 NS5 protein sequences from four DENV serotypes of Chinese isolates. For the HLA-A allele, five of the 21 epitopes were conserved with ≥90% conservancy ([Table 2](#pone.0138729.t002){ref-type="table"}), including ^200^CVYNMMGKREK^210^ (94.84%, A\*11:01), ^515^MYFHRRDLRL^524^ (98.71%, A\*24:02), ^225^WYMWLGAR^232^ (99.35%, A\*33:03), ^516^YFHRRDLR^523^ (98.71%, A\*33:03), and ^284^DTAGWDTR^291^(98.06%, A\*33:03). For the HLA-B allele, four of the 53 epitopes were conserved with ≥90% conservancy ([Table 3](#pone.0138729.t003){ref-type="table"}), including ^234^LEFEALGF^241^ (96.77%, B\*13:01), ^92^AMTDTTPF^99^ (98.06%, B\*15:01, B\*15:02 and B\*46:01), ^262^LHKLGYIL^269^ (92.90%, B\*38:02), and ^538^VPTSRTTWSI^547^ (90.97%, B\*51:01). For the HLA-C allele, nine of the 42 epitopes were conserved with ≥90% conservancy ([Table 4](#pone.0138729.t004){ref-type="table"}), including ^514^LMYFHRRDL^522^ (98.71%, C\*01:02), ^514^LMYFHRRDLRL^524^ (98.71%, C\*14:02 and C\*01:02), ^92^AMTDTTPF^99^ (98.06%, C\*03:02 and C\*15:02), ^362^FTNMEAQL^369^ (94.84%, C\*03:04 and C\*08:01), ^225^WYMWLGAR^232^ (99.35%, C\*04:01), ^234^LEFEALGF^241^(96.77%, C\*04:01), ^361^TFTNMEAQL^369^ (94.84%, C\*04:01), ^515^MYFHRRDL^522^ (98.71%, C\*14:02), and ^515^MYFHRRDLRL^524^ (98.71%, C\*14:02).

Since the HLA allele frequencies vary among populations due to different genetic backgrounds, to design an effective vaccine, we should consider the candidate epitopes that specifically bind with the prevalent HLA molecules in the target population where the vaccine will be employed. Therefore, here we examined the population coverage of the proposed epitope vaccine candidate in a Chinese population. The results showed that the epitope ^92^AMTDTTPF^99^ (B\*15:01, B\*15:02, B\*46:01, C\*03:02, and C\*15:02) has the highest percentage of population coverage (47.16%), followed by ^200^CVYNMMGKREK^210^ (A\*11:01, 43.48%), ^362^FTNMEAQL^369^ (C\*03:04 and C\*08:01, 36.60%), ^514^LMYFHRRDLRL^524^ (C\*01:02 and C\*14:02, 33.53%), ^515^MYFHRRDLRL^524^ (A\*24:02 and C\*14:02, 28.69%), and ^514^LMYFHRRDL^522^ (C\*01:02, 27.68%) in China ([Table 5](#pone.0138729.t005){ref-type="table"}). It is worth noting that the combination of the epitopes ^92^AMTDTTPF^99^ (B\*15:01, B\*15:02, B\*46:01, C\*03:02 and C\*15:02), ^200^CVYNMMGKREK^210^ (A\*11:01), ^362^FTNMEAQL^369^ (C\*03:04 and C\*08:01), and ^514^LMYFHRRDLRL^524^ (C\*01:02 and C\*14:02) could vaccinate \>90% of the Chinese population, suggesting that the four epitopes are better candidates for a multiple T-cell epitope-based vaccine. These highly conserved HLA restricted epitopes with acceptable population coverage could be putative epitope vaccine candidates in their combinations to elicit DENV-specific T-cell responses. Finally, to avoid the autoimmune response, all of the predicted class I HLA-binding antigenic epitopes were analyzed for their homology with human proteome, but no epitope was homologous with human proteome. Based on these results, we proposed that the combination of these highly conserved epitopes could be as universal CD8^+^ T-cell epitope vaccine candidates to induce DENV-specific T-cell responses against four DENV serotypes that are endemic in China.

10.1371/journal.pone.0138729.t005

###### Population coverage rate (%) for the highly conserved epitopes that could be as multiple epitope-based universal vaccine candidates.

![](pone.0138729.t005){#pone.0138729.t005g}

  Epitope candidates   Position (aa) [^a^](#t005fn001){ref-type="table-fn"}   HLA class I alleles                                                    Population coverage (%)
  -------------------- ------------------------------------------------------ ---------------------------------------------------------------------- -------------------------
  AMTDTTPF             92--99                                                 HLA-B\*15:01, HLA-B\*15:02, HLA-B\*46:01, HLA-C\*03:02, HLA-C\*15:02   47.16
  CVYNMMGKREK          200--210                                               HLA-A\*11:01                                                           43.48
  FTNMEAQL             362--369                                               HLA-C\*03:04, HLA-C\*08:01                                             36.60
  LMYFHRRDLRL          514--524                                               HLA-C\*01:02, HLA-C\*14:02                                             33.53
  MYFHRRDLRL           515--524                                               HLA-A\*24:02, HLA-C\*14:02                                             28.69
  LMYFHRRDL            514--522                                               HLA-C\*01:02                                                           27.68
  WYMWLGAR             225--232                                               HLA-A\*33:03, HLA-C\*04:01                                             18.46
  LEFEALGF             234--241                                               HLA-B\*13:01, HLA-C\*04:01                                             17.48
  YFHRRDLR             516--523                                               HLA-A\*33:03                                                           9.78
  DTAGWDTR             284--291                                               HLA-A\*33:03                                                           9.78
  TFTNMEAQL            361--369                                               HLA-C\*04:01                                                           9.62
  VPTSRTTWSI           538--547                                               HLA-B\*51:01                                                           7.39
  MYFHRRDL             515--522                                               HLA-C\*14:02                                                           6.91
  LHKLGYIL             262--269                                               HLA-B\*38:02                                                           5.22

^a^The epitopes location in NS5 protein are from accession number: KC131142.1.

Conclusion {#sec013}
==========

HLA-restricted epitopes for prophylactic or therapeutic vaccines against infectious diseases to induce a T-cell response that eliminates infected cells is a promising vaccine strategy. In this study, we identified 14 universal CD8^+^ T-cell epitope candidates using immunoinformatic approach, and they are highly conserved among all four DENV serotypes that are endemic in China. The combination of four epitopes, including ^92^AMTDTTPF^99^ (B\*15:01, B\*15:02, B\*46:01, C\*03:02 and C\*15:02), ^200^CVYNMMGKREK^210^ (A\*11:01), ^362^FTNMEAQL^369^ (C\*03:04 and C\*08:01), and ^514^LMYFHRRDLRL^524^ (C\*01:02 and C\*14:02), could vaccinate \>90% of individuals in China. These epitopes are valuable T-cell epitope-based vaccine candidates for the development of a universal dengue vaccine that is capable of eliciting specific and robust protective T-cell responses against four DENV serotype variants. In conclusion, our study highlights that it is possible to design an epitope-based universal vaccine against all four DENV serotypes based on protective CD8^+^ T-cell-mediated cellular immune responses.
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